Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24103712 | 1.00 | ESR1 (0.50) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL17965954 | 1.00 | ESR1 (0.50) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL30362774 | 1.00 | ESR1 (0.50) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL30362794 | 0.93 | ESR1 (0.55) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL244280 | 0.93 | ESR1 (0.55) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL24103707 | 0.93 | ESR1 (0.55) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL17965956 | 0.93 | ESR1 (0.55) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL28193659 | 0.92 | CYP3A4 (0.49) | ESR1ESR2CYP19A1MAPTMAPK1 | |
| SCHEMBL6092580 | 0.86 | CYP3A4 (0.54) | ESR1ESR2CYP19A1MAPTLMNA | |
| SCHEMBL28194176 | 0.84 | ESR1 (0.49) | ESR1ESR2CYP19A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809618-B1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2013-07-17 | — | — | EP | claimed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | claimed |
| US-8080675-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4164632-A1 | COMBINATION THERAPIES | MEI Pharma, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-107427003-B | Combination therapy | 梅制药公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2010045674-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | NOVOGEN RESEARCH PTY LTD (AU) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-2120925-A1 | METHOD FOR INDUCING AUTOPHAGY | Novogen Research Pty. Ltd. (AU) | 2009-11-25 | — | — | EP | disclosed |
| EP-1809618-A4 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008113100-A1 | METHOD FOR INDUCING AUTOPHAGY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-25 | — | — | WO | disclosed |
| EP-1809618-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty Ltd (AU) | 2007-07-25 | — | — | EP | disclosed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032086-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | ESR1 2467/4885ESR2 1403/4885CYP19A1 3739/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ESR1 3784/4885ESR2 2187/4885CYP19A1 2123/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1699/4885ESR2 1586/4885CYP19A1 2946/4885 |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | CDYL, XPA, TP53 | ESR1 1699/4885ESR2 1586/4885CYP19A1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.